What is chloroquine and how does it work against malaria
Chloroquine is a synthetic antimalarial drug that has been used for decades to prevent and treat malaria caused by the parasite Plasmodium, primarily in areas where the parasite remains sensitive to the drug. It belongs to a class of medications known as 4-aminoquinolines and works by interfering with the growth and reproduction of the parasite within red blood cells. In areas where malaria is present, chloroquine has historically been a first-line treatment for uncomplicated Plasmodium vivax and Plasmodium ovale infections, as well as susceptible strains of Plasmodium malariae and Plasmodium knowlesi. Its use for Plasmodium falciparum is now limited to regions where the parasite has not developed resistance. Because chloroquine can also prevent infection when taken before exposure, it has been used for malaria chemoprophylaxis in areas without resistance.
Understanding when chloroquine remains effective is essential, because widespread use in areas with chloroquine-resistant parasites has led to treatment failure and contributed to changes in global malaria treatment guidelines. This overview explains how chloroquine works, where it is still recommended, how to take it, common side effects, and important safety precautions based on current evidence.
Chloroquine malaria treatment overview and key facts
Chloroquine has long been a cornerstone of malaria control, but its role has shifted as resistance patterns have changed. Below is a quick reference to key aspects of chloroquine in malaria treatment and prevention.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Primary use for malaria | Treatment and prophylaxis against chloroquine-sensitive Plasmodium species | Clinical guidelines and drug labels |
| Key resistance concern | Widespread resistance in Plasmodium falciparum; limited use in P. vivax in some regions | WHO and CDC surveillance reports |
| Typical adult prophylaxis dose | 500 mg base once weekly, starting before travel and continuing after | Standardized dosing references |
| Typical adult treatment dose | 1 g base initially, then 500 mg base at 6, 18, and 24 hours (acute treatment) | Regulatory and prescribing information |
| Common side effects | Nausea, headache, abdominal pain, pruritus, and ocular changes with long-term use | Adverse event data and reviews |
| Major contraindication | Glucose-6-phosphate dehydrogenase (G6PD) deficiency in some severe forms; caution in psoriasis and porphyria | Prescribing guidelines |
| Pregnancy considerations | Considered safe at recommended doses for malaria treatment and prophylaxis when benefits outweigh risks | Regulatory and clinical guidance |
| Important monitoring | Long-term use may require eye exams for retinal changes | Safety advisories |
How chloroquine works inside the malaria parasite
Chloroquine exerts its antimalarial effect by accumulating in the parasite’s digestive vacuole, where it raises the internal pH and interferes with the detoxification of heme, a toxic byproduct of hemoglobin digestion. By disrupting this process, chloroquine prevents the parasite from breaking down hemoglobin and reproducing within red blood cells. This action helps clear parasites from the bloodstream in sensitive strains. However, resistance often arises through mutations that alter parasite transport mechanisms, reducing drug accumulation in the vacuole and rendering standard doses less effective or ineffective.
Where chloroquine is still recommended for malaria today
Current guidance reflects regional differences in parasite susceptibility. Chloroquine remains a recommended option for treating and preventing malaria in specific areas where Plasmodium species have not developed resistance. Travel medicine clinicians and national malaria programs rely on up-to-date maps to decide whether chloroquine is appropriate for a given destination.
Regions where chloroquine may still be used for treatment or prophylaxis
In many parts of the world, chloroquine is no longer effective against Plasmodium falciparum. In contrast, some regions report continued chloroquine-sensitive Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale infections. Decisions about using chloroquine should always be based on the most recent information from authoritative sources for the specific travel or treatment location.
Chloroquine dosing for malaria prevention (chemoprophylaxis)
When used to prevent malaria, chloroquine is taken before, during, and after exposure to mosquito-borne transmission. Adherence to the schedule is important to maintain protective drug levels. Travelers should begin chloroquine prophylaxis at least one week before entering an area where the drug is effective and continue taking it for four weeks after leaving the area.
- Adults: 500 mg (base) by mouth, once weekly, on the same day each week.
- Children: Dosed based on body weight, typically 5 mg base per kilogram once weekly, adjusted for age and weight.
- Timing: Start one week before travel, take weekly while there, and continue for four weeks after returning.
Missed doses reduce protection, so travelers should follow the schedule closely. If a dose is missed, the person should take it as soon as remembered and then resume the regular weekly schedule, without doubling doses.
Chloroquine dosing for treatment of malaria infection
For treatment of confirmed chloroquine-sensitive malaria, adults typically receive a higher initial dose followed by smaller doses to complete the course. The exact regimen can vary based on the species involved and local guidance, so confirmation of susceptibility and consultation with a clinician or local guidelines is essential.
- Adults (treatment): An initial dose of 1 g (base) followed by 500 mg (base) at 6, 18, and 24 hours.
- Children: Weight-based dosing under medical supervision, usually a higher initial dose followed by divided doses over 24 to 48 hours.
- Important: Treatment should only be managed by a healthcare provider who can confirm the local parasite susceptibility and monitor for response and side effects.
Common side effects and safety considerations with chloroquine
Chloroquine is generally well tolerated at recommended doses, but some people experience side effects, and long-term use requires additional monitoring. Travelers and patients should be aware of potential adverse reactions and when to seek medical attention.
Common short-term side effects
Side effects are often dose-related and can include gastrointestinal symptoms, headache, and skin sensations. These are usually mild and may improve as the body adjusts to the medication.
- Nausea and vomiting
- Headache
- Abdominal pain or cramps
- Itchy skin (pruritus)
- Dizziness
Long-term use and potential ocular effects
Prolonged use of chloroquine, especially at higher doses, has been associated with retinal changes that can affect vision. Regular eye examinations are recommended for individuals requiring long-term therapy. Early detection can help prevent serious vision problems.
Contraindications and special precautions
Chloroquine is not suitable for everyone. Certain medical conditions may increase the risk of severe side effects. People with the following situations typically need careful evaluation before using chloroquine:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (some forms may be severe).
- History of psoriasis or porphyria.
- Known hypersensitivity to chloroquine or related compounds.
- Use with caution in people with liver or kidney impairment under medical supervision.
Pregnant people should use chloroquine only when the potential benefit justifies the potential risk, based on guidance from a healthcare professional. For people traveling to or living in areas where malaria is present, the benefits of preventing malaria often outweigh the risks when used appropriately.
Resistance patterns and why they matter for treatment
Chloroquine resistance in Plasmodium falciparum emerged in the late 20th century and is now widespread in many regions. Resistance is less common in Plasmodium vivax, but reports of reduced chloroquine response have appeared in some areas. When resistance is present, chloroquine fails to clear parasites and may lead to prolonged illness. This is a key reason that current guidelines reserve chloroquine for regions where susceptibility is documented.
Health authorities and malaria programs monitor resistance through surveillance and adjust treatment recommendations accordingly. Clinicians rely on local guidance, updated periodically from national and international sources, to choose between chloroquine and alternative medicines. Travelers should seek advice from a clinician or travel medicine clinic well before departure to determine the best malaria prevention options for their destination.
Key takeaways on chloroquine for malaria
Chloroquine remains an important antimalarial medicine where parasites are still susceptible. It is effective for both preventing and treating certain types of malaria when used as directed and when resistance is not a concern. Because resistance is common in many parts of the world, its use must be guided by up-to-date regional recommendations. Awareness of dosing schedules, potential side effects, and the need for eye exams during prolonged use helps ensure safe and effective use. Travelers and patients should rely on current guidance from trusted sources and work closely with healthcare professionals to choose the most appropriate malaria prevention or treatment strategy.